Capricor Therapeutics (CAPR) Set to Announce Earnings on Wednesday

Capricor Therapeutics (NASDAQ:CAPR) is scheduled to announce its earnings results after the market closes on Wednesday, August 7th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter.

Capricor Therapeutics (NASDAQ:CAPR) last posted its earnings results on Monday, May 13th. The biotechnology company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.20). The company had revenue of $4.91 million during the quarter, compared to analysts’ expectations of $10.00 million. Capricor Therapeutics had a negative net margin of 89.72% and a negative return on equity of 231.68%. On average, analysts expect Capricor Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Capricor Therapeutics Price Performance

NASDAQ CAPR opened at $4.06 on Thursday. Capricor Therapeutics has a 12 month low of $2.68 and a 12 month high of $8.22. The company has a market capitalization of $129.84 million, a price-to-earnings ratio of -4.67 and a beta of 4.00. The firm’s fifty day moving average price is $5.02 and its 200 day moving average price is $5.13.

Wall Street Analyst Weigh In

Several brokerages recently commented on CAPR. Cantor Fitzgerald reiterated an “overweight” rating and issued a $8.00 price objective on shares of Capricor Therapeutics in a research note on Tuesday, May 14th. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Capricor Therapeutics in a research report on Tuesday, July 2nd. Oppenheimer began coverage on shares of Capricor Therapeutics in a research report on Friday, May 17th. They set an “outperform” rating and a $14.00 price target on the stock. LADENBURG THALM/SH SH lifted their price target on shares of Capricor Therapeutics from $24.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday, May 14th. Finally, StockNews.com downgraded shares of Capricor Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 14th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to MarketBeat.com, Capricor Therapeutics has an average rating of “Moderate Buy” and an average target price of $21.75.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.